Epicore BioNetworks Inc. Announces Stock Option Grants
CALGARY, Oct. 26 /CNW/ - Epicore BioNetworks Inc. announces that it has granted stock options to an officer and to employees of the company. The number of options granted is 500,000, which is equivalent to 2.1% of Epicore's issued common stock. Of these options 100,000 were issued to an officer. Under the terms of the Epicore Stock Option Plan, options may be issued from time to time in any amount up to a maximum of 4,704,247 Epicore common shares. These options have an exercise price of Cdn $0.12 and expire in five years.
Epicore BioNetworks Inc. is a leading producer of environmental biotechnology and animal nutrition products. It manufactures in the USA and markets worldwide to a variety of industries to reduce environmental pollution and increase operational productivity.
Epicore BioNetworks Inc. is a public corporation with a registered office in Calgary, Alberta, Canada and with shares listed on the TSX Venture Exchange (symbol EBN). [Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.]
This press release contains forward-looking statements that involve significant risks and uncertainties. The actual results, performance or achievements of the Company might differ materially from the results, performance or achievements of the Company expressed or implied by such forward-looking statements. Such forward-looking statements include, without limitation, those regarding the development plans of the Company and the expected timing and results of such development. We can provide no assurance that such development will proceed as currently anticipated or that the expected timing or results of such development will be realized. We are subject to various risks, including the uncertainties of product development, markets for our products and regulatory review, our need for additional capital to fund our operations, our reliance on collaborative partners, our history of losses, and other risks inherent in the biotechnology industry.
For further information:
Mr. William P. Long (Chief Executive Officer)
USA. Tel: 609-267-9118,
Email: [email protected]
Share this article